S699
Clinical – Lower GI
ESTRO 2026
median follow-up duration comparable to the overall cohort. Conclusion: Disease progression rates observed to date are consistent with findings from international studies. Further long-term monitoring is imperative to validate the sustainability of these outcomes, particularly considering the recent updates from the RAPIDO trial, which indicate lower rates of local control in the intervention arm. Notably, sustained responses were observed in patients who achieved a clinical complete response and subsequently entered a WaW protocol. References: Romesser PB et al. Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. J Clin OncolVan der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM-K, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. Radiother Oncol Dijkstra EA et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long- course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg Keywords: Total neoadjuvant therapy; RAPIDO; Short course Digital Poster Highlight 1786 Sex-specific differences in outcomes and toxicity after total neoadjuvant therapy for locally advanced rectal cancer Maike Trommer 1,2 , Melanie Schneider 3 , Jan-Niklas Becker 4 , Bernd Frerker 5 , Samuel M. Vorbach 6 , Felix Ehret 7,8 , Markus Diefenhardt 9,10 , Fabian Schunn 11 , Maria-Elena von Gruben 12 , Marcel Büttner 13,14 , Alexander Rühle 15,16 , Ezgi Ceren Sahin 17 , Kynann Aninditha 18 , Daphne Schepers-von Ohlen 19 , Justus Kaufmann 20 , Alina Depardon 21 , Hai Minh Ha 22 , Christopher Kessler 23 , Adrianna Cieslak 24,25 , Simon Trommer 26 , Simone Ferdinandus 1,27 , Alexander Fabian 28 , Florian Rißner 29 , Klaus Pietschmann 30,31 , Georg Wurschi 30,31 1 Department of Radiation Oncology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. 2 Department I of Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, Cologne, Germany. 3 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 4 Department of Radiotherapy, Hannover Medical School, Hannover, Germany.
received treatment with curative intent during the period when SCRT was the established standard of care in the institution. Patient medical records were reviewed to extract relevant clinical data and follow-up information regarding disease progression. All statistical analyses were performed using R statistical software. Results:
Between April 2020 and March 2023, 63 patients were treated for rectal cancer in a TNT scheme including SCRT. 52% of them were female, and the median age was 65 years. Tumor staging at presentation included T2 (2%), T3 (69%), and T4 (27%), with 92% of patients presenting with positive lymph nodes. 75 % of patients were treated using VMAT, and the remaining using 3D tecnique. The median follow-up for the entire cohort was 38 months. At 3 years, progression free survival was 66 % and overall survival was 81 %. 42 patients were submitted to surgery, with a median interval from RT end to surgery of 275 days. Furthermore, 18 patients were managed under a "Watch and Wait" (WaW) protocol. Within this WaW subgroup, 77% of the patients remained alive and surgery-free at a
Made with FlippingBook - Share PDF online